KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dynavax Technologies (DVAX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Dynavax Technologies (DVAX) over the last 17 years, with Q3 2025 value amounting to $160.2 million.

  • Dynavax Technologies' Cash & Equivalents rose 3428.67% to $160.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.2 million, marking a year-over-year increase of 3428.67%. This contributed to the annual value of $95.9 million for FY2024, which is 3619.67% down from last year.
  • As of Q3 2025, Dynavax Technologies' Cash & Equivalents stood at $160.2 million, which was up 3428.67% from $99.1 million recorded in Q2 2025.
  • Dynavax Technologies' 5-year Cash & Equivalents high stood at $436.2 million for Q4 2021, and its period low was $51.7 million during Q1 2025.
  • Its 5-year average for Cash & Equivalents is $168.3 million, with a median of $154.5 million in 2023.
  • Per our database at Business Quant, Dynavax Technologies' Cash & Equivalents skyrocketed by 125998.82% in 2021 and then tumbled by 6082.8% in 2025.
  • Dynavax Technologies' Cash & Equivalents (Quarter) stood at $436.2 million in 2021, then tumbled by 53.69% to $202.0 million in 2022, then decreased by 25.61% to $150.3 million in 2023, then plummeted by 36.2% to $95.9 million in 2024, then skyrocketed by 67.13% to $160.2 million in 2025.
  • Its Cash & Equivalents was $160.2 million in Q3 2025, compared to $99.1 million in Q2 2025 and $51.7 million in Q1 2025.